Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of safinamide (SAF).
Background: OPC proved to be effective in treating end-of-dose MF in PD patients [1,2]. The OPTIPARK study evaluated OPC 50 mg in a heterogeneous population of patients treated in real-world conditions .
Method: OPTIPARK was a prospective, open-label, single-arm trial conducted in Germany and the UK. Patients with MF received OPC 50 mg in addition to current antiparkinsonian treatment. Primary efficacy 3-month endpoint was Clinician’s-Global-Impression-of-Change (CGI-C). Secondary efficacy endpoints included Patient’s-CGI-C (PGI-C), 8-item PD-Questionnaire (PDQ-8), Unified PD Rating Scale (UPDRS) and Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs). This post-hoc analysis evaluated the influence of baseline use of SAF in patients who completed the study for each outcome.
Results: Overall, 393 (82.4%) patients completed the 3-month endpoint (completers-set, Table 1). Of these, patients not using SAF at baseline experienced greater improvements on CGI-C and PGI-C, when compared to patients using SAF at baseline (Table 2). Except for PDQ-8, patients using SAF at baseline experienced greater improvements on UPDRS-II and III, and non-motor symptoms (NMSS), when compared to patients not using SAF at baseline (Table 3). Similar incidence of TEAEs considered at least possibly related to OPC were reported for both subgroups (Table 3).
Conclusion: Overall, these findings indicate that patients may benefit from using OPC 50 mg with or without safinamide as adjunctive therapy to levodopa.
References: 1. Ferreira et al., Lancet Neurology 2016; 15(2):154-165. 2. Lees et al., JAMA Neurol. 2017; 74(2):197-206. 3. Reichmann et al., Transl Neurodegener. 2020;9(1):9
To cite this abstract in AMA style:N. Pavese, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva. Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/effectiveness-of-opicapone-in-parkinsons-disease-patients-with-motor-fluctuations-according-to-baseline-use-of-safinamide-findings-from-the-real-world-optipark-study/. Accessed December 7, 2023.
« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/effectiveness-of-opicapone-in-parkinsons-disease-patients-with-motor-fluctuations-according-to-baseline-use-of-safinamide-findings-from-the-real-world-optipark-study/